-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 10, the NMPA official website updated the latest drug approval information.
Yangzijiang won the production approval for dexmedetomidine hydrochloride and sodium chloride injection and tirofiban hydrochloride and sodium chloride injection.
The approval of 3 types of imitations is regarded as over-review
.
Dexmedetomidine is a sedative species with nearly 4 billion, and tirofiban is also a "billion-level" antithrombotic drug
.
Figure 1: Yangtze River’s latest approved products.
Source: NMPA official website.
Figure 2: Sales of dexmedetomidine and tirofiban (unit: 100 million yuan).
Source: Meinenet.
Midine is an α2 adrenergic receptor agonist.
It is mainly used for tracheal intubation and sedation of mechanical ventilation in patients undergoing general anesthesia.
Currently, there are only injections on the market
.
Before 2018, Hengrui was a leader in dexmedetomidine hydrochloride injection, with a market share of more than 80%; at the end of 2018, the 4+7 pilot project opened the prelude to the collection, and Yangtze River was deemed to have passed the review according to the new classification.
The company won the bid exclusively for this variety, and there were still no new competitors in the expansion of the alliance.
Yangtze River successfully won most of the market by taking advantage of the gathering wind, and now it has become the overlord of this variety with a share of more than 90%
.
In 2020, the sales of dexmedetomidine hydrochloride injection will also rise to close to 4 billion yuan in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
The half-year growth rate reached double digits again, and the market potential continued to be released
.
Figure 3: Earlier approvals for dexmedetomidine hydrochloride and sodium chloride injection.
Source: One-click search on Mynet.
com In 2021, Hengrui Medicine won the first domestic imitation of dexmedetomidine hydrochloride and sodium chloride injection.
, And then Chengdu Better Pharmaceutical was approved, and Yangtze River became the third company
.
The approval of the new product is expected to further consolidate Yangtze River’s leading position in this product, and at the same time, a new round of competition between Yangtze River and Hengrui is also starting.
.
Tirofiban is a non-peptide platelet glycoprotein (GP) Ⅱb/Ⅲa receptor antagonist, clinically mainly used for coronary angioplasty or intracoronary plaque resection in patients with coronary ischemic syndrome , To prevent and treat related cardiac ischemia complications; also for patients with unstable angina or non-Q-wave myocardial infarction (in combination with heparin or aspirin) to prevent cardiac ischemic events
.
According to data from Menet.
com, in 2020, the sales of tirofiban in China's public medical institutions will exceed 400 million yuan.
Currently, Lunanbet Pharmaceuticals and Yuanda Pharmaceuticals (China) lead the market
.
Figure 4: Tirofiban has been reviewed earlier.
Source: Mynet.
com consistency evaluation database.
Currently all relevant products on the market are injections.
Among them, tirofiban hydrochloride sodium chloride injection has been reviewed by 5 companies earlier.
All the supplementary applications have been approved, and the approval of Yangzijiang according to the new classification this time is regarded as over-evaluation.
If the product is included in the seventh batch of national procurement catalogs, Yangzijiang is expected to quickly seize the market after winning the bid
.
Source: NMPA official website, Minet.
com database.
Statistics are as of December 10th.
Please correct me if there are any errors or omissions
.
Yangzijiang won the production approval for dexmedetomidine hydrochloride and sodium chloride injection and tirofiban hydrochloride and sodium chloride injection.
The approval of 3 types of imitations is regarded as over-review
.
Dexmedetomidine is a sedative species with nearly 4 billion, and tirofiban is also a "billion-level" antithrombotic drug
.
Figure 1: Yangtze River’s latest approved products.
Source: NMPA official website.
Figure 2: Sales of dexmedetomidine and tirofiban (unit: 100 million yuan).
Source: Meinenet.
Midine is an α2 adrenergic receptor agonist.
It is mainly used for tracheal intubation and sedation of mechanical ventilation in patients undergoing general anesthesia.
Currently, there are only injections on the market
.
Before 2018, Hengrui was a leader in dexmedetomidine hydrochloride injection, with a market share of more than 80%; at the end of 2018, the 4+7 pilot project opened the prelude to the collection, and Yangtze River was deemed to have passed the review according to the new classification.
The company won the bid exclusively for this variety, and there were still no new competitors in the expansion of the alliance.
Yangtze River successfully won most of the market by taking advantage of the gathering wind, and now it has become the overlord of this variety with a share of more than 90%
.
In 2020, the sales of dexmedetomidine hydrochloride injection will also rise to close to 4 billion yuan in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
The half-year growth rate reached double digits again, and the market potential continued to be released
.
Figure 3: Earlier approvals for dexmedetomidine hydrochloride and sodium chloride injection.
Source: One-click search on Mynet.
com In 2021, Hengrui Medicine won the first domestic imitation of dexmedetomidine hydrochloride and sodium chloride injection.
, And then Chengdu Better Pharmaceutical was approved, and Yangtze River became the third company
.
The approval of the new product is expected to further consolidate Yangtze River’s leading position in this product, and at the same time, a new round of competition between Yangtze River and Hengrui is also starting.
.
Tirofiban is a non-peptide platelet glycoprotein (GP) Ⅱb/Ⅲa receptor antagonist, clinically mainly used for coronary angioplasty or intracoronary plaque resection in patients with coronary ischemic syndrome , To prevent and treat related cardiac ischemia complications; also for patients with unstable angina or non-Q-wave myocardial infarction (in combination with heparin or aspirin) to prevent cardiac ischemic events
.
According to data from Menet.
com, in 2020, the sales of tirofiban in China's public medical institutions will exceed 400 million yuan.
Currently, Lunanbet Pharmaceuticals and Yuanda Pharmaceuticals (China) lead the market
.
Figure 4: Tirofiban has been reviewed earlier.
Source: Mynet.
com consistency evaluation database.
Currently all relevant products on the market are injections.
Among them, tirofiban hydrochloride sodium chloride injection has been reviewed by 5 companies earlier.
All the supplementary applications have been approved, and the approval of Yangzijiang according to the new classification this time is regarded as over-evaluation.
If the product is included in the seventh batch of national procurement catalogs, Yangzijiang is expected to quickly seize the market after winning the bid
.
Source: NMPA official website, Minet.
com database.
Statistics are as of December 10th.
Please correct me if there are any errors or omissions
.
